Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

Trial Profile

Multiple-dose, Double-blind, Double-dummy Study to Compare the Efficacy and Safety of Oral Doses of Cinacalcet Hydrochloride With Intravenous Doses of Etelcalcetide) in Asian Hemodialysis Subjects With Secondary Hyperparathyroidism

Recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Aug 2018

At a glance

  • Drugs Etelcalcetide (Primary) ; Cinacalcet
  • Indications Secondary hyperparathyroidism
  • Focus Therapeutic Use
  • Sponsors Amgen
  • Most Recent Events

    • 31 May 2018 Status changed from not yet recruiting to recruiting.
    • 30 Jan 2018 Planned End Date changed from 19 Jul 2019 to 29 Jul 2019.
    • 30 Jan 2018 Planned primary completion date changed from 19 Jul 2019 to 29 Jul 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top